Revumenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Relapsed/Refractory Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Company guidance: data expected 4Q26 (Syndax, 2 Nov 2026). “New revumenib data expected in 4Q26 from clinical trials and real-world studies spanning the acute leukemia treatment continuum and multiple genetic subtypes –” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Acute Myeloid Leukemia
Phase 2/3 (1)
Relapsed/Refractory Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
Phase 2 (7)
Acute Lymphoblastic Leukemia
NCT07636564 · SWOG Cancer Research Network
2026-10-14 – 2032-04-16 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
What this study did
Acute Myeloid Leukemia
NCT07563010 · Center for International Blood and Marrow Transplant Research
2026-12 – 2031-06 · Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
What this study did
NCT07686107 · Therapeutic Advances in Childhood Leukemia Consortium
2026-08-31 – 2030-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT07605949 · UNC Lineberger Comprehensive Cancer Center
2026-12 – 2028-07 · Leukemia Acute Myeloid
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT05761171 · Children's Oncology Group
2024-01-08 – 2027-12-31 · Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
What this study did
Other / comorbidity
NCT06229912 · M.D. Anderson Cancer Center
2024-06-04 – 2028-12-01 · Leukemia, HOX Gene
What this study did
Phase 1/2 (6)
Acute Lymphoblastic Leukemia
NCT07356154 · Memorial Sloan Kettering Cancer Center
2026-01-16 – 2029-01-16 · Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
What this study did
Acute Myeloid Leukemia
NCT06284486 · M.D. Anderson Cancer Center
2024-09-23 – 2028-12-30 · Acute Myeloid Leukemia
What this study did
NCT05360160 · M.D. Anderson Cancer Center
2022-10-14 – 2026-12-01 · Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07734077 · John Mascarenhas
2026-12-01 – 2028-12-01 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT05731947 · Syndax Pharmaceuticals
2023-04-04 – 2025-06-30 · Colorectal Cancer, Solid Tumors
What this study did
Phase 1 (12)
Acute Lymphoblastic Leukemia
NCT07283640 · M.D. Anderson Cancer Center
2026-11-18 – 2031-08-31 · Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
What this study did
NCT07498465 · Children's Oncology Group
2026-09-10 – 2028-11-12 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
What this study did
NCT06575296 · City of Hope Medical Center
2024-12-31 – 2028-04-29 · Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Leukemia, Childhood Acute Leukemia of Ambiguous Lineage, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
What this study did
NCT05326516 · Syndax Pharmaceuticals
2022-03-09 – 2024-07-29 · Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
What this study did
Acute Myeloid Leukemia
NCT06313437 · Richard Stone, MD
2024-12-06 – 2028-03-02 · Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
What this study did
NCT05886049 · National Cancer Institute (NCI)
2024-06-20 – 2027-12-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Secondary Acute Myeloid Leukemia
What this study did
NCT06226571 · Syndax Pharmaceuticals
2024-05-21 – 2027-02 · Acute Myeloid Leukemias
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT06177067 · St. Jude Children's Research Hospital
2024-04-19 – 2029-02 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
What this study did
NCT06222580 · Uma Borate
2024-02-20 – 2027-02-28 · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07923071 · Syndax Pharmaceuticals
2026-11 – 2032-01 · Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia
What this study did
NCT07052994 · M.D. Anderson Cancer Center
2026-05-21 – 2026-05-21 · Pediatric Acute Leukemia
What this study did
NCT05406817 · Syndax Pharmaceuticals
2022-08-05 – 2024-11-18 · Acute Leukemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Revumenib: this drugApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Icovamenib
Phase 2(overall)
Small moleculeMenin
Partial signal(overall)
NCT05153330: Interim COVALENT-101 data as of the July 24, 2023 cutoff: 26 patients with relapsed or refractory acute leukemia (24 with AML, 2 with ALL) were enrolled. BMF-219 has generally been well tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related toxicities. Among efficacy-evaluable patients, 2 of 5 achieved a complete remission (1 CR, 1 CRi).
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
PRGN-3006Phase 1Cell therapyCD33Weak signal
NCT03927261: PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed.
CamibirstatDiscontinuedSmall moleculeSMARCA4/SMARCA2 (BRG1/BRM ATPase subunits)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 64 furthest-along competitors are listed; 67 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Revumenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05360160 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06284486 · CT.gov ↗
What to watch
2027 (7)
January 2027 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06177067 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01-31 · NCT06222580 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT06226571 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-02 · NCT06313437 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-15 · NCT04065399 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05886049 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT05761171 · CT.gov ↗
What to watch
2028 (4)
April 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-04-29 · NCT06575296 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-07 · NCT07605949 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia MyelofibrosisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07734077 · CT.gov ↗
What to watch
Phase 2Leukemia, HOX GeneRecruiting
Est. primary completion 2028-12-01 · NCT06229912 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-16 · NCT07356154 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06 · NCT07211958 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2029-08-31 · NCT07283640 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-12-13 · NCT06652438 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07686107 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 1Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed LeukemiaNot yet recruiting
Est. primary completion 2030-01 · NCT07923071 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-06 · NCT07563010 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch

See the full readout calendar ↗